Long-term results of HBV and HCV infection in patients with blood diseases

Tat'yana Tsyrenovna Garmaeva; Гармаева Татьяна Цыреновна; Sergey Mikhaylovich Kulikov; Куликов Сергей Михайлович; Elena Alekseevna Mikhaylova; Михайлова Елена Алексеевна; Eduard Georgievich Gemdzhyan; Гемджян Эдуард Георгиевич; Tat'yana Vladimirovna Gaponova; Гапонова Татьяна Владимировна; Lyudmila Olegovna Grumbkova; Грумбкова Людмила Олеговна; Natal'ya Gurgenovna Yaroslavtseva; Ярославцева Наталья Гургеновна; Tat'yana Alekseevna Tupoleva; Туполева Татьяна Алексеевна; Alla Vladimirovna Somova; Сомова Алла Владимировна; Tat'yana Viktorovna Makarik; Макарик Татьяна Викторовна; Ol'ga Anatol'evna Glinshchikova; Глинщикова Ольга Анатольевна; Irina Serafimovna Fevraleva; Февралева Ирина Серафимовна; Andrey Borisovich Sudarikov; Судариков Андрей Борисович; Feliks Petrovich Filatov; Филатов Феликс Петрович; Valeriy Grigor'evich Savchenko; Савченко Валерий Григорьевич; T Ts Garmaeva; Garmaeva T Ts; S M Kulikov; Kulikov S M; E A Mikhailova; Mikhailova E A; E G Gemdzhyan; Gemdzhyan E G; T V Gaponova; Gaponova T V; L O Grumbkova; Grumbkova L O; N G Yaroslavtseva; Yaroslavtseva N G; T A Tupoleva; Tupoleva T A; A V Somova; Somova A V; T A Makarik; Makarik T A; O A Glinschikova; Glinschikova O A; I S Fevraleva; Fevraleva I S; A B Sudarikov; Sudarikov A B; F P Filatov; Filatov F P; V G Savchenko; Savchenko V G

Long-term results of HBV and HCV infection in patients with blood diseases

Authors: Garmaeva T.T.¹, Kulikov S.M.¹, Mikhaylova E.A.¹, Gemdzhyan E.G.¹, Gaponova T.V.¹, Grumbkova L.O.¹, Yaroslavtseva N.G.¹, Tupoleva T.A.¹, Somova A.V.¹, Makarik T.V.¹, Glinshchikova O.A.¹, Fevraleva I.S.¹, Sudarikov A.B.¹, Filatov F.P.¹, Savchenko V.G.¹, Garmaeva TT.², Kulikov SM², Mikhailova EA², Gemdzhyan EG², Gaponova TV², Grumbkova LO², Yaroslavtseva NG², Tupoleva TA², Somova AV², Makarik TA², Glinschikova OA², Fevraleva IS², Sudarikov AB², Filatov FP², Savchenko VG²
Affiliations:
2. Hematological Research Center, Moscow
Issue: Vol 83, No 7 (2011)
Pages: 17-26
Section: Editorial
URL: https://ter-arkhiv.ru/0040-3660/article/view/30860

Cite item

Full Text

Abstract
About the authors
References
Statistics

Abstract

Aim. To specify trends in clinical and laboratory manifestations of virus hepatitis B and C (HBV and HCV) in patients with blood diseases from the moment of the first positive specific tests for HBV and HCV markers; to assess effects of HBV and HCV infection on efficacy of treatment of blood disease treatment, i.e. lifespan of patients with hematological diseases.
Material and methods. The study enrolled 257 patients: 205 with acute leukemia - AL, 40 with lymphoproliferative diseases, 4 - with CML and 8 - others; 8 healthy bone marrow donors. The patients were admitted to Russian Hematological Research Center in 2004-2006. Follow-up median was 253 days. A total of 7800 biological samples were studied, among them about 4000 tests for HBV DNA and HCV RNA.
Results. Positive tests for specific markers of HBV and HCV were absent only in 78 (29.4%) patients. Positive markers of coinfection were detected in 57 (32.8%) of 174 patients with HBV infection and in 81.4% of 70 patients with HCV infection. Probability of detection of HCV markers after positive tests for HBV markers and vice versa is about 3 times higher than probability of their isolated detection. Among patients infected with HBV symptoms of hepatitis B are likely to appear in 56% patients to day 500 of follow-up from the date of the first positive specific test. Median of the interval between the first positive test for HBV markers and probable clinical signs of hepatitis was 30 days. Among patients with HCV infection, 85% develop hepatitis to follow-up day 300 since the date of the first specific positive test. Almost 100% patients infected with two viruses develop hepatitis to follow-up day 600. Median of the interval between the first positive test for HBV and HCV markers and probable hepatitis picture was 47 days. Overall 3-year survival of AL patients was 40%, of patients with lymphoproliferative diseases - 58%. Overall 7-month survival was 75% in AA patients. HBV infection in patients with blood disease is associated with high risk of death, especially in AA and AL. Association between HCV infection and survival is not proved.
Conclusion. A high rate of clinical realization of viral hepatitis B and C, especially in coinfection, calls for virological and clinical monitoring of patients with any positive test for HBV and HCV markers.

Keywords

viral hepatitis B and C, survival, hematological malignancies

References

Stramer S. L., Wend U., Candotti D. et al. Nucleic acid testing to detect HBV infection in blood donors. N. Engl. J. Med. 2011; 364: 236-247.
Shi Y. H., Shi C. H. Molecular characteristics and stages of chronic hepatitis В virus infection. Wld J. Gastroenterol. 2009; 15(25): 3099-3105.
Hoofnagle J. H., Doo E., Liang T. J. et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075.
NIH Consensus statement on management of hepatitis C: 2002. NIH Consens. State Sci. Statements 2002; 19(3): 1-46.
Raimondo G., Allain J. P., Brunetto M. R. et al. Statements from Taormina expert meeting on occult hepatitis В virus infection. J. Hepatol 2008; 49: 652-657.
Chu C. J., Lee S. D. Hepatitis В virus/hepatitis С virus coinfection: epidemiology, clinical features, viral interactions and treatment. J. Gastroenterol. Hepatol. 2008; 23(4): 512-520.
Jamma S., Hussain G., Lau D. T.-Y. Curren concepts of HBV/ HCV coinfection: coexistence, but not necessarily in harmony. Curr. Hepat. Rep. 2010; 9(4): 260-269.
Firpi R. J., Nelson D. R. Management of viral hepatitis in hematologic malignancies. Blood Rev. 2008; 22(3): 117-126.
Anderson L. A., Pfeiffer R., Warren J. L. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol. Biomarkers Prev. 2008; 17(11): 3069-3075.
Гармаева Т. Ц., Куликов С. М., Михайлова Е. А. и др. Динамика инфицирования вирусами гепатитов В и С больных с заболеваниями системы крови. Гематол. и трансфузиол. 2009; 54(5): 16-23.
Гармаева Т. Ц., Куликов С. М., Карякин А. В. и др. Мониторирование факторов риска и индикаторов инфицированности вирусами гепатитов В и С гематологических больных. Гематол. и трансфузиол. 2006; 1: 23-27.
Михайлова Е. А., Клясова Г. А., Устинова Е. Н., Савченко В. Г. Программная терапия апластической анемии: Клинические рекомендации. М.: ГУ ГНЦ РАМН; 2008.
Савченко В. Г. Острые лейкозы и беременность - некоторые постулаты. Тер. арх. 2009; 7: 5-7.
Богомолов Б. П. К истории клинического диагноза инфекционных болезней. Тер. арх. 2009; 4: 44-46.
Castellino S., Lensing S., Riely C. et al. The epidemiology of chronic hepatitis С infection in suivivors of childhood cancer: an update of the St Jude Childrens Research Hospital hepatitis С seropositive cohort. Blood 2004; 103: 2460-2466.
Bertoletti A., Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003; 38: 4-13.
Асратян А. А., Исаева О. В., Михайлов М. И. Тенденции и анализ эпидемиологической ситуации по парентеральным вирусным гепатитам В и С в Российской Федерации. Журн. микробиол. 2005; 4: 40-45.
Zuckerman E., Zuckerman T., Douer D. et. al. Liver dysfunction in patients infected with hepatitis С virus undergoing chemotherapy for hematologic malignancies. Cancer 1998; 83(6): 1224-1230.
Takai S., Tsurumi H., Ando K. Prevalence of hepatitis В and С virus infection in haematological malignancies and liver injury following chemotherapy. Eur. J. Haematol. 2005; 74(2): 158- 165.
Kawatani T., Suou T., Tajima F. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematological malignancies. Eur. J. Haematol. 2001; 67: 45-50.
Николаева Л. И. Специфический гуморальный иммунитет при вирусном гепатите С. Дис. ... д-ра биол. наук. М.; 2006.
Рейзис А. Р. Вирусные гепатиты у больных с онкогематологическими заболеваниями. В кн.: Волкова М. А. (ред.). Клиническая онкогематология. М.: Медицина; 2007. 1077-1089.
Dreier J., Kroger М., Diekmann J. et al. Low-level viraemia of hepatitis В virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus. Med. 2004; 14: 97-103.
Weber B., Melchior W., Gehrke R. Hepatitis В virus markers in anti-HBc only positive individuals. J. Med. Virol. 2001; 64(3): 312-319.
Niederbauser С., Talegbani В., Graziani M. et al. Blood donor screening: how to decrease the risk of transfusion-transmiteed hepatitis В virus. Swiss. Med. Wkly 2008; 138 (9-10): 134- 141.
Francisci D., Falcinelli F., Schiaroli E. et al. Management of hepatitis В virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010; 38(1): 58-61.
SAS Institute Inc. SAS 9.1.3. Сary, NC: SAS Institute Inc.; 2004.
Anderson J. R., Cain K. C., Gelber R. D. Analysis of survival by tumor response. J. Clin. Oncol. 1983; 1: 710-719.
Wieland S. F., Chisari F. V. Stealth and cunning: hepatitis В and hepatitis С viruses. J. Virol. 2005; 79(15): 9369-9380.
Chung R. T. Hepatitis С and В viruses: the new opportunists in HIV infection. International AIDS Society-USA March New Jork. 2006. 78-83.
Thimme R., Spangenberg H. C., Blum H. E. Hepatitis В or hepatitis С and human immunodeficiency virus infection. J. Hepatol. 2005; 42: 37-44.
Гайдамака Н. В., Паровичникова Е. Н., Завалишина Л. Э. и др. Длительные аплазии костного мозга после химиотерапии у больных острыми лейкозами. Тер. арх. 2010; 7: 29-34.

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Long-term results of HBV and HCV infection in patients with blood diseases

Full Text

Abstract

Keywords

About the authors

References

This website uses cookies